Follow the people · Insider
da Silva Jorge Santos
da Silva Jorge Santos files insider transactions with the SEC as a chief executive officer of MoonLake Immunotherapeutics (MLTX). We hold 5 disclosed purchases and sales filed since 3 October 2023, 3 of them in the last 90 days.
- Files forMLTX
- Disclosed buys and sells5 in all, 3 in the last 90 days
- Last disclosure13 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 October 2023 — 10 July 2026Chief Executive Officer · MoonLake Immunotherapeutics (MLTX)26 Form 4 lines · source: SEC Form 4
Everything they disclosed
26 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 33,936 shares of MoonLake ImmunotherapeuticsSEC Form 413 July 2026Class A ordinary shares, par value $0.0001 per share · traded 9 July 2026 · filed 13 July 2026
- ▼ sold on the open market 68,289 shares of MoonLake ImmunotherapeuticsSEC Form 413 July 2026Class A ordinary shares, par value $0.0001 per share · traded 10 July 2026 · filed 13 July 2026
- ▼ sold on the open market 47,775 shares of MoonLake ImmunotherapeuticsSEC Form 42 July 2026Class A ordinary shares, par value $0.0001 per share · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 98,127 shares of MoonLake ImmunotherapeuticsSEC Form 414 April 2026Class A ordinary shares, par value $0.0001 per share · traded 10 April 2026 · filed 14 April 2026
- ▼ sold on the open market 51,873 shares of MoonLake ImmunotherapeuticsSEC Form 414 April 2026Class A ordinary shares, par value $0.0001 per share · traded 13 April 2026 · filed 14 April 2026
- was granted 520,342 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 49 January 2026Stock Option (Right to Buy) · traded 7 January 2026 · filed 9 January 2026
- was granted 520,342 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 49 January 2026Stock Option (Right to Buy) · traded 7 January 2026 · filed 9 January 2026
- converted 5,836 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 422 December 2025Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 19 December 2025 · filed 22 December 2025
- converted 196,316 shares of MoonLake ImmunotherapeuticsSEC Form 422 December 2025Class A ordinary shares, par value $0.0001 per share · traded 19 December 2025 · filed 22 December 2025
- returned to the issuer 196,316 shares of MoonLake ImmunotherapeuticsSEC Form 422 December 2025Class C ordinary shares, par value $0.0001 per share · traded 19 December 2025 · filed 22 December 2025
- ▼ sold on the open market 130,000 shares of MoonLake ImmunotherapeuticsSEC Form 410 December 2025Class A ordinary shares, par value $0.0001 per share · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 70,000 shares of MoonLake ImmunotherapeuticsSEC Form 410 December 2025Class A ordinary shares, par value $0.0001 per share · traded 9 December 2025 · filed 10 December 2025
- was granted 95,763 shares of MoonLake ImmunotherapeuticsSEC Form 43 March 2025Class A ordinary shares, par value $0.0001 per share · traded 27 February 2025 · filed 3 March 2025
- ▼ sold on the open market 62,810 shares of MoonLake ImmunotherapeuticsSEC Form 429 February 2024Class A ordinary shares, par value $0.0001 per share · traded 27 February 2024 · filed 29 February 2024
- ▼ sold on the open market 56,065 shares of MoonLake ImmunotherapeuticsSEC Form 429 February 2024Class A ordinary shares, par value $0.0001 per share · traded 28 February 2024 · filed 29 February 2024
- ▼ sold on the open market 4,740 shares of MoonLake ImmunotherapeuticsSEC Form 429 February 2024Class A ordinary shares, par value $0.0001 per share · traded 29 February 2024 · filed 29 February 2024
- ▼ sold on the open market 1,125 shares of MoonLake ImmunotherapeuticsSEC Form 423 February 2024Class A ordinary shares, par value $0.0001 per share · traded 21 February 2024 · filed 23 February 2024
- ▼ sold on the open market 20,000 shares of MoonLake ImmunotherapeuticsSEC Form 420 February 2024Class A ordinary shares, par value $0.0001 per share · traded 15 February 2024 · filed 20 February 2024
- ▼ sold on the open market 20,000 shares of MoonLake ImmunotherapeuticsSEC Form 420 February 2024Class A ordinary shares, par value $0.0001 per share · traded 16 February 2024 · filed 20 February 2024
- ▼ sold on the open market 20,000 shares of MoonLake ImmunotherapeuticsSEC Form 420 February 2024Class A ordinary shares, par value $0.0001 per share · traded 20 February 2024 · filed 20 February 2024
- converted 90,000 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 43 October 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 1 October 2023 · filed 3 October 2023
- converted 4,164 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 43 October 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 1 October 2023 · filed 3 October 2023
- converted 3,027,483 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class A ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- returned to the issuer 3,027,483 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class C ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- converted 140,071 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class A ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- returned to the issuer 140,071 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class C ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.